Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ORIC Pharmaceuticals
Biotech
Oric chases Pfizer into phase 3 hailing prostate cancer edge
Investors sent the stock down as they digested Oric’s phase 1b data and choice of pivotal treatment regimen.
Nick Paul Taylor
Apr 1, 2026 9:53am
Career oncologist makes Big Pharma leap to BMS—Chutes & Ladders
Aug 22, 2025 8:30am
Oric lays off 20% of workforce in focus on clinical-stage drugs
Aug 13, 2025 6:20am
Biogen CMO Maha Radhakrishnan joins Sofinnova—Chutes & Ladders
Aug 9, 2024 8:30am
Pfizer boosts ORIC shares with multiple myeloma collaboration
Dec 22, 2022 11:20am
FDA shores up executive team with 2 hires—Chutes & Ladders
Jul 1, 2022 9:30am
